Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ZD1839 ('Iressa') as an anticancer agent.

J Baselga1, S D Averbuch

  • 1Medical Oncology Service, Vail d'Hebron University Hospital, Barcelona, Spain.

Drugs
|December 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO's new strategic plan: our society's road to the future of oncology.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

ZD1839 (Iressa) is a targeted therapy blocking cancer cell growth. Early trials show it is well-tolerated and effective, especially for non-small cell lung cancer (NSCLC).

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) signaling pathways are crucial for cancer cell proliferation and survival.
  • Targeting EGFR-tyrosine kinase offers a potential strategy for cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of ZD1839 (Iressa), a selective EGFR-tyrosine kinase inhibitor.
  • To explore the potential of ZD1839 in various cancer types, with a focus on non-small cell lung cancer (NSCLC).

Main Methods:

  • Preclinical studies involving tumor cell lines and xenografts.
  • Phase I clinical trials in patients with advanced cancers.
  • Assessment of ZD1839's impact on tumor growth and patient tolerability.

Related Experiment Videos

Main Results:

  • ZD1839 demonstrated reversible tumor growth inhibition and delay in preclinical models.
  • Co-administration with cytotoxic agents enhanced ZD1839's anti-tumor activity.
  • Phase I trials indicated an acceptable safety profile and promising clinical efficacy, particularly in NSCLC patients.

Conclusions:

  • ZD1839 is a promising targeted therapy for cancer treatment.
  • Its efficacy is notable in non-small cell lung cancer (NSCLC).
  • Further clinical development, including Phase III trials for NSCLC, is warranted.